Clinical trial · Interventional
Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 2 study conducted in two sequential stages: The first stage is an Italian single institution, single arm, pilot study, aimed at exploring the activity of the combination T and P in myxoid liposarcoma patients who achieved a stable disease after a minimum of 4 cycles of T alone. If a minimum required activity will be demonstrated from the first stage, the second stage of the study will be conducted;otherwise, the study will be stopped. The second stage is an Italian open-label, multicenter, randomized, double arm, phase II trial, aimed at evaluating the combination of T and P in myxoid liposarcoma and G1 or G2 dedifferentiated liposarcomas compared to the standard treatment with T alone. Patients will be randomized with a 1:1 ratio to treatments arms as specified below: * Control arm (A): T alone * Experimental arm (B): T in combination with P
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liposarcoma, Dedifferentiated | Dedifferentiated Liposarcoma | ONTOLOGY_EXACT | 0.98 |
| Liposarcoma, Myxoid | Myxoid Liposarcoma | ONTOLOGY_EXACT | 0.98 |
| Liposarcoma, Round Cell | Round Cell Liposarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pioglitazone Oral Product | Drug | — | UNRESOLVED |
| Trabectedin | Drug | Trabectedin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Trabectedin in combination with Pioglitazone
- description
- Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
- interventionNames
- Drug: Trabectedin
- Drug: Pioglitazone Oral Product
Primary outcomes (1)
- measure
- Objective response (OR) in patients with myxoid liposarcomas according to RECIST criteria or CHOI criteria
- timeFrame
- From the date of the enrollment up to 24 months
- description
- The primary activity endpoint is the number of responders. Patients will be considered as responders if they reach a CR or PR as best response during treatment according to RECIST criteria or according to Choi criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosis of myxoid/round cell liposarcomas 2. Histological diagnosis confirmation by a reference centre 3. Age ≥ 18 years 4. ECOG PS ≤2 5. One or more previous systemic treatments employing anthracyclines +/- ifosfamide (unless one or both are clinically contraindicated) 6. Four or more previous cycles of T with a stable disease as defined by RECIST criteria 7. Recovery from toxic effects of prior therapies to NCI CTC Grade 1 or higher 8. Provision of signed informed consent Exclusion Criteria: 1. Pregnant or breast-feeding women 2. Partial response or progression disease as per RECIST criteria to the previous treatment with T 3. Inadequate haematological, renal and liver functions 4. History of other malignancies (except basal cell carcinoma or cervical carcinoma in situ, adequately treated), unless in remission from 5 years or more and judged of negligible potential of relapse 5. Known central nervous system (CNS) metastases 6. Active viral hepatitis or chronic liver disease 7. Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within one year before enrolment, uncontrolled arterial hypertension or arrhythmias 8. Active major infection 9. Other serious concomitant illnesses
References
Publications (0)
Data not yet available